Article (Scientific journals)
Traitement de la maladie de Crohn de l'adulte par anticorps anti-tumor necrosis factor-alpha (TNF alpha)
Belaiche, Jacques; Louis, Edouard
2000In Revue Médicale de Liège, 55 (9), p. 827-32
Peer reviewed
 

Files


Full Text
Traitement de la maladie de Crohn de l'adulte... 2000-RML-827.pdf
Publisher postprint (806.32 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Crohn's disease (CD) is a chronic inflammatory disease of the bowel characterized by segmental transmural inflammation and granulomatous changes. TNF alpha is a member of a large family of proteins and receptors that are involved in immune regulation. It is a proinflammatory and immunoregulatory cytokine synthesized by monocytes, macrophages, and T cells. TNF alpha plays an early central role in the cytokine cascade of the inflammatory process. Recently, chimeric monoclonal antibodies that inhibits TNF alpha have been used in the treatment of Crohn's disease. Infliximab has been the most largely used antibody. It is commercialized in the USA and has recently obtained an European marketing approvement. Infliximab is indicated for the treatment of moderately to severely active CD in patients having an inadequate response to conventional therapy. Clinical trials have demonstrated efficacy when the agent is initiated as a 5 mg/kg single intravenous infusion. In patients with fistulizing CD, administration of 2 subsequent 5 mg/kg doses 2 and 6 weeks after the initial dose appears to be efficacious. Limited clinical data also suggest that infliximab retreatment regimen restores response and maintains remission rates. Infliximab appears to be well tolerated. To date, very little is known about the potential for long-term toxicity with infliximab therapy.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Belaiche, Jacques ;  Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Louis, Edouard  ;  Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Language :
French
Title :
Traitement de la maladie de Crohn de l'adulte par anticorps anti-tumor necrosis factor-alpha (TNF alpha)
Alternative titles :
[en] Treatment of Crohn Disease in Adults with Tumor Necrosis Factor-Alpha (Tnf-Alpha) Antibodies
Publication date :
September 2000
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
55
Issue :
9
Pages :
827-32
Peer reviewed :
Peer reviewed
Available on ORBi :
since 21 November 2009

Statistics


Number of views
207 (1 by ULiège)
Number of downloads
133 (0 by ULiège)

Scopus citations®
 
3
Scopus citations®
without self-citations
3

Bibliography


Similar publications



Contact ORBi